Three HCRN studies accepted to ASCO 2017
Abstracts from three Hoosier Cancer Research Network studies were accepted to the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, June 2-6 at the McCormick […]
Abstracts from three Hoosier Cancer Research Network studies were accepted to the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, June 2-6 at the McCormick […]
Hoosier Cancer Research Network investigators highlighted an HCRN melanoma study as a poster presentation during the Society for Melanoma Research 16th International Congress, Nov. 20-23, […]
This month, Hoosier Cancer Research Network features our member institution University of Rochester Medical Center – Wilmot Cancer Institute and Ruth O’Regan, MD, the Charles […]
Two Indiana University School of Medicine hematology-oncology fellows are digging deep into timely cancer research questions, with research support provided by the George and Sarah […]
Two Hoosier Cancer Research Network studies, GU14-182 and MEL17-309, will be presented during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 […]
A new Hoosier Cancer Research Network study may help researchers learn whether the order in which two drugs are given has any effect on progression-free […]
Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma Status: Closed to Accrual
Hoosier Cancer Research Network, formerly known as Hoosier Oncology Group, recently honored Matthew Galsky, MD, as recipient of the Danny Danielson Translational Innovation Award. The […]
Researchers participating HCRN BRE21-516, also known as BRIDGET, had their work featured as a Trials in Progress abstract at the Society for NeuroOncology Annual Summit. The study focuses […]
Hoosier Cancer Research Network investigators presented a poster highlighting GI17-319, a gastric and esophageal adenocarcinoma study, during the AACR Annual Meeting 2021. A single arm, […]
Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center, along with colleagues from Fox Chase Cancer Center, Icahn School of Medicine at Mount […]
A new Hoosier Cancer Research Network study is exploring the effects of pembrolizumab in treating metastatic urothelial cancer. The study, known as GU14-182, will compare […]
Three Hoosier Cancer Research Network genitourinary studies were featured during the American Society of Clinical Oncology Genitourinary (GU) Cancers Symposium in San Francisco, CA on […]
Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing Status: Closed to Accrual
In a new journal article published online ahead of print in Supportive Care in Cancer, Hoosier Cancer Research Network investigators reported on results of QL12-153, […]
Based on encouraging preliminary data, researchers at Mayo Clinic in Rochester, Minn., are leading a randomized multi-site phase II study for adults with metastatic, recurrent, […]
A single arm phase II study, LUN15-299, for patients who have been previously treated for mesothelioma is being conducted by the Hoosier Cancer Research Network […]
In a phase II study reported in the Journal of Clinical Oncology, Hoosier Cancer Research Network (HCRN) investigators report that switch maintenance pembrolizumab leads to […]
Indiana University Melvin and Bren Simon Cancer Center is leading a phase II clinical trial that will test the PD-L1 checkpoint inhibitor atezolizumab plus chemotherapy […]
Having good mentors is something that this year’s George and Sarah Jane Fisher Young Investigator Award recipient, Shahid Ahmed, MD, values greatly. Through his personal […]
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter